Chronic kidney disease delays VLDL-apoB-100 particle catabolism: Potential role of apolipoprotein C-III

Journal of Lipid Research

Volumn 50, Issue 12, 2009, Pages 2524-2531

  Chan, Doris T ^a,b   Dogra, Gursharan K ^b   Irish, Ashley B ^c   Ooi, Esther M ^a   Barrett, P Hugh ^a   Chan, Dick C ^a   Watts, Gerald F ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^c ROYAL PERTH HOSPITAL   (Australia)

Author keywords

Central adiposity; Insulin resistance; Kinetic analysis; Lipids

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN B100; APOLIPOPROTEIN C3; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; IMMUNOASSAY; MALE; OBESITY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN TRANSPORT; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 70849133524     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.P900003-JLR200     Document Type: Article

References (46)

1. Go, A. S., G. M. Chertow, D. Fan, C. E. McCulloch, and C. Y. Hsu. 2004. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 351: 1296-1305.
2. Samuelsson, O., P. O. Attman, C. Knight-Gibson, B. Kron, R. Larsson, H. Mulec, L. Weiss, and P. Alaupovic. 1994. Lipoprotein abnormalities without hyperlipidaemia in moderate renal insufficiency. Nephrol. Dial. Transplant. 9: 1580-1585.
3. Sarwar, N., J. Danesh, G. Eiriksdottir, G. Sigurdsson, N. Wareham, S. Bingham, S. M. Boekholdt, K. T. Khaw, and V. Gudnason. 2007. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation. 115: 450-458.
4. Ginsberg, H. N. 2002. New perspectives on atherogenesis: role of abnormal triglyceride-rich lipoprotein metabolism. Circulation. 106: 2137-2142.
5. Chan, P. C., J. Persaud, Z. Varghese, D. Kingstone, R. A. Baillod, and J. F. Moorhead. 1989. Apolipoprotein B turnover in dialysis patients: its relationship to pathogenesis of hyperlipidemia. Clin. Nephrol. 31: 88-95.
6. Ikewaki, K., J. R. Schaefer, M. E. Frischmann, K. Okubo, T. Hosoya, S. Mochizuki, B. Dieplinger, E. Trenkwalder, H. Schweer, F. Kronenberg, et al. 2005. Delayed in vivo catabolism of intermediate-density lipoprotein and low-density lipoprotein in hemodialysis patients as potential cause of premature atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 25: 2615-2622.
7. Prinsen, B. H. C. M., T. J. Rabelink, J. A. Romijn, P. H. Bisschop, M. M. J. De Barse, J. De Boer, T. W. van Haeften, P. H. R. Barrett, R. Berger, and M. de Sain-van der Velden. 2004. A broad-based metabolic approach to study VLDL apoB100 metabolism in patients with ESRD and patients treated with peritoneal dialysis. Kidney Int. 65: 1064-1075.
8. Batista, M. C., F. K. Welty, M. R. Diffenderfer, M. J. Sarnak, E. J. Schaefer, S. Lamon-Fava, B. F. Asztalos, G. G. Dolnikowski, M. E. Brousseau, and J. B. Marsh. 2004. Apolipoprotein A-I, B-100, and B-48 metabolism in subjects with chronic kidney disease, obesity, and the metabolic syndrome. Metabolism. 53: 1255-1261.
9. Chen, J., P. Muntner, L. L. Hamm, V. Fonseca, V. Batuman, P. K. Whelton, and J. He. 2003. Insulin resistance and risk of chronic kidney disease in nondiabetic US adults. J. Am. Soc. Nephrol. 14: 469-477.
10. Kobayashi, S., K. Maesato, H. Moriya, T. Ohtake, and T. Ikeda. 2005. Insulin resistance in patients with chronic kidney disease. Am. J. Kidney Dis. 45: 275-280.
11. Lee, P., D. O'Neal, B. Murphy, and J. Best. 1997. The role of abdominal adiposity and insulin resistance in dyslipidemia of chronic renal failure. Am. J. Kidney Dis. 29: 54-65.
12. Goff, D.C., Jr., R. B. D'Agostino, Jr., S. M. Haffner, and J. D. Otvos. 2005. Insulin resistance and adiposity influence lipoprotein size and subclass concentrations. Results from the Insulin Resistance Atherosclerosis Study. Metabolism. 54: 264-270.
13. Adiels, M., J. Boren, M. J. Caslake, P. Stewart, A. Soro, J. Westerbacka, B. Wennberg, S. O. Olofsson, C. Packard, and M. R. Taskinen. 2005. Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemia. Arterioscler. Thromb. Vasc. Biol. 25: 1697-1703.
14. Gill, J. M. R., J. C. Brown, D. Bedford, D. M. Wright, J. Cooney, D. A. Hughes, C. J. Packard, and M. J. Caslake. 2004. Hepatic production of VLDL1 but not VLDL2 is related to insulin resistance in normoglycaemic middle-aged subjects. Atherosclerosis. 176: 49-56.
15. Vaziri, N. D. 2006. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am. J. Physiol. Renal Physiol. 290: F262-F272.
16. Ginsberg, H. N., N. A. Le, I. J. Goldberg, J. C. Gibson, A. Rubinstein, P. Wang-Iverson, R. Norum, and W. V. Brown. 1986. Apolipoprotein B metabolism in subjects with defi ciency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J. Clin. Invest. 78: 1287-1295.
17. Arnon, R., E. Sehayek, T. Vogel, and S. Eisenberg. 1991. Effects of exogenous apo E-3 and of cholesterol-enriched meals on the cellular metabolism of human chylomicrons and their remnants. Biochim. Biophys. Acta. 1085: 336-342.
18. Irish, A. 1998. Cardiovascular disease, fibrinogen and the acute phase response: Associations with lipids and blood pressure in patients with chronic renal disease. Atherosclerosis. 137: 133-139.
19. Gruber, P. J., A. Torres-Rosado, M. L. Wolak, and T. Leff. 1994. Apo CIII gene transcription is regulated by a cytokine inducible NF-kappa B element. Nucleic Acids Res. 22: 2417-2422.
20. Wang, Z., S. J. Nicholls, E. R. Rodriguez, O. Kummu, S. Horkko, J. Barnard, W. F. Reynolds, E. J. Topol, J. A. DiDonato, and S. L. Hazen. 2007. Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat. Med. 13: 1176-1184.
21. Chan, D. C., G. F. Watts, T. G. Redgrave, T. A. Mori, and P. H. Barrett. 2002. Apolipoprotein B-100 kinetics in visceral obesity: associations with plasma apolipoprotein C-III concentration. Metabolism. 51: 1041-1046.
22. Stone, N. J., S. Bilek, and S. Rosenbaum. 2005. Recent national cholesterol education program adult treatment panel III update: adjustments and options. Am. J. Cardiol. 96: 53E-59E.
23. Beghin, L., N. Duhal, P. Poulain, P. Hauw, B. Lacroix, J. M. Lecerf, J. P. Bonte, J. C. Fruchart, and G. Luc. 2000. Measurement of apolipoprotein B concentration in plasma lipoproteins by combining selective precipitation and mass spectrometry. J. Lipid Res. 41: 1172-1176.
24. Lindgren, F. T. JLHF. 1972. The isolation and quantitative analysis of serum lipoproteins. In Blood Lipids and Lipoproteins. G. J. Nelson, editor. John Wiley & Sons, New York. 181-274.
25. Dwyer, K. P., P. H. R. Barrett, D. Chan, J. I. Foo, G. F. Watts, and K. D. Croft. 2002. Oxazolinone derivative of leucine for GC-MS: a sensitive and robust method for stable isotope kinetic studies of lipoproteins. J. Lipid Res. 43: 344-349.
26. Uchida, Y., Y. Kurano, and S. Ito. 1998. Establishment of monoclonal antibody against human Apo B-48 and measurement of Apo B-48 in serum by ELISA method. J. Clin. Lab. Anal. 12: 289-292.
27. Millar, J. S., C. Maugeais, K. Ikewaki, D. M. Kolansky, P. H. R. Barrett, E. C. Budreck, R. C. Boston, N. Tada, S. Mochizuki, J. C. Defesche, et al. 2005. Complete deficiency of the low-density lipoprotein receptor is associated with increased apolipoprotein B-100 production. Arterioscler. Thromb. Vasc. Biol. 25: 560-565.
28. Chan, D. C., G. F. Watts, P. H. R. Barrett, L. J. Beilin, T. G. Redgrave, and T. A. Mori. 2002. Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia. Diabetes. 51: 2377-2386.
29. Packard, C. J., T. Demant, J. P. Stewart, D. Bedford, M. J. Caslake, G. Schwertfeger, A. Bedynek, J. Shepherd, and D. Seidel. 2000. Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions. J. Lipid Res. 41: 305-318.
30. Lee, D. M., C. Knight-Gibson, O. Samuelsson, P. O. Attman, C. S. Wang, and P. Alaupovic. 2002. Lipoprotein particle abnormalities and the impaired lipolysis in renal insufficiency. Kidney Int. 61: 209-218.
31. Kimak, E., and J. Solski. 2002. apoA- and apoB-containing lipoproteins and Lp(a) concentration in non-dialyzed patients with chronic renal failure. Ren. Fail. 24: 485-492.
32. Arnadottir, M., H. Thysell, J. Dallongeville, J. C. Fruchart, and P. Nilsson-Ehle. 1995. Evidence that reduced lipoprotein lipase activity is not a primary pathogenetic factor for hypertriglyceridemia in renal failure. Kidney Int. 48: 779-784.
33. Holdsworth, G., J. Stocks, P. Dodson, and D. J. Galton. 1982. An abnormal triglyceride-rich lipoprotein containing excess sialylated apolipoprotein C-III. J. Clin. Invest. 69: 932-939.
34. Stenvinkel, P., and A. Alvestrand. 2002. Inflammation in end-stage renal disease: sources, consequences, and therapy. Semin. Dial. 15: 329-337.
35. Navarro, M. A., R. Carpintero, S. Acin, J. M. Arbones-Mainar, L. Calleja, R. Carnicer, J.C. Surra, M. A. Guzman-Garcia, N. Gonzalez-Ramon, M. Iturralde, et al. 2005. Immune-regulation of the apolipoprotein A-I/C-III/A-IV gene cluster in experimental inflammation. Cytokine. 31: 52-63.
36. Tornvall, P., G. Olivecrona, F. Karpe, A. Hamsten, and T. Olivecrona. 1995. Lipoprotein lipase mass and activity in plasma and their increase after heparin are separate parameters with different relations to plasma lipoproteins. Arterioscler. Thromb. Vasc. Biol. 15: 1086-1093.
37. Kraus, L. M., and A. P. Kraus. 2001. Carbamoylation of amino acids and proteins in uremia. Kidney Int. 78 (Suppl.): S102-S107.
38. Miyata, T., S. Sugiyama, A. Saito, and K. Kurokawa. 2001. Reactive carbonyl compounds related uremic toxicity ("carbonyl stress"). Kidney Int. 78 (Suppl.): S25-S31.
39. Adeli, K., and G. F. Lewis. 2008. Intestinal lipoprotein overproduction in insulin-resistant states. Curr. Opin. Lipidol. 19: 221-228.
40. Hayashi, T., T. Hirano, T. Taira, A. Tokuno, Y. Mori, S. Koba, and M. Adachi. Remarkable increase of apolipoprotein B48 level in diabetic patients with end-stage renal disease. Atherosclerosis. 197: 154-158.
41. Brunzell, J. D., W. R. Hazzard, D. Porte, Jr., and E. L. Bierman. 1973. Evidence for a common, saturable, triglyceride removal mechanism for chylomicrons and very low density lipoproteins in man. J. Clin. Invest. 52: 1578-1585.
42. Campos, H., C. Khoo, and F. M. Sacks. 2005. Diurnal and acute patterns of postprandial apolipoprotein B-48 in VLDL, IDL, and LDL from normolipidemic humans. Atherosclerosis. 181: 345-351.
43. Charlesworth, J. A., A. D. Kriketos, J. E. Jones, J. H. Erlich, L. V. Campbell, and P. W. Peake. 2005. Insulin resistance and postprandial triglyceride levels in primary renal disease. Metabolism. 54: 821-828.
44. Weintraub, M., A. Burstein, T. Rassin, M. Liron, Y. Ringel, S. Cabili, M. Blum, G. Peer, and A. Iaina. 1992. Severe defect in clearing post-prandial chylomicron remnants in dialysis patients. Kidney Int. 42: 1247-1252.
45. Hokanson, J. E., and M. A. Austin. 1996. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J. Cardiovasc. Risk. 3: 213-219.
46. Taskinen, M. R. 2003. Diabetic dyslipidemia: from basic research to clinical practice. Diabetologia. 46: 733-749.